同仁堂国药公布2024年度业绩 多维度提升综合竞争力 筑牢高质量发展根基

证券日报网
28 Mar

2025年3月28日,北京同仁堂国药有限公司(“同仁堂国药”或“公司”,股份代号:3613.HK)欣然公布公司及其附属公司(统称为“同仁堂国药集团”)截至2024年12月31日止年度(“本年”)之经审计的合并业绩。2024年,同仁堂国药集团持续拓展业务版图,深化品牌影响力,同时优化内部管理,提升运营效率,推动经营水平和发展质量同步提升。本年,同仁堂国药集团实现收入1,611.6百万港元,同比增长...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10